CIABATTI, ELENA
 Distribuzione geografica
Continente #
NA - Nord America 3.661
EU - Europa 1.771
AS - Asia 1.642
SA - Sud America 292
AF - Africa 94
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 2
Totale 7.466
Nazione #
US - Stati Uniti d'America 3.553
IT - Italia 589
CN - Cina 544
SG - Singapore 525
SE - Svezia 380
HK - Hong Kong 270
BR - Brasile 254
DE - Germania 219
GB - Regno Unito 181
BG - Bulgaria 135
VN - Vietnam 107
CA - Canada 85
TR - Turchia 64
FI - Finlandia 63
RU - Federazione Russa 59
CI - Costa d'Avorio 46
IN - India 39
FR - Francia 38
BE - Belgio 24
UA - Ucraina 24
JP - Giappone 23
SN - Senegal 15
ES - Italia 11
AR - Argentina 10
BD - Bangladesh 10
PL - Polonia 10
KR - Corea 8
MX - Messico 8
NL - Olanda 8
UZ - Uzbekistan 8
CZ - Repubblica Ceca 7
EC - Ecuador 7
LT - Lituania 7
NG - Nigeria 7
VE - Venezuela 7
ZA - Sudafrica 7
SA - Arabia Saudita 6
CO - Colombia 5
ID - Indonesia 5
KE - Kenya 5
PK - Pakistan 5
EG - Egitto 4
GR - Grecia 4
KZ - Kazakistan 4
MA - Marocco 4
AE - Emirati Arabi Uniti 3
AT - Austria 3
CH - Svizzera 3
CL - Cile 3
DO - Repubblica Dominicana 3
IL - Israele 3
IQ - Iraq 3
IR - Iran 3
PH - Filippine 3
TW - Taiwan 3
AU - Australia 2
BS - Bahamas 2
EU - Europa 2
HR - Croazia 2
IE - Irlanda 2
PR - Porto Rico 2
PY - Paraguay 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
XK - ???statistics.table.value.countryCode.XK??? 2
AZ - Azerbaigian 1
BB - Barbados 1
BJ - Benin 1
BM - Bermuda 1
DK - Danimarca 1
ET - Etiopia 1
HN - Honduras 1
JM - Giamaica 1
JO - Giordania 1
KW - Kuwait 1
LY - Libia 1
MD - Moldavia 1
MY - Malesia 1
NI - Nicaragua 1
OM - Oman 1
PA - Panama 1
PE - Perù 1
PS - Palestinian Territory 1
SR - Suriname 1
TG - Togo 1
Totale 7.466
Città #
Ashburn 408
Dallas 301
Serra 275
Fairfield 272
Woodbridge 270
Singapore 266
Hong Kong 265
Santa Clara 262
Chandler 237
Houston 209
Ann Arbor 205
Beijing 155
Sofia 131
Seattle 128
Shanghai 118
New York 104
Wilmington 101
Boardman 89
Cambridge 85
Princeton 70
Ottawa 67
Los Angeles 61
Milan 57
London 55
Munich 53
Medford 47
Abidjan 46
Lawrence 44
Florence 43
Des Moines 37
Lancaster 29
Bremen 27
Dearborn 27
Izmir 26
Pisa 26
Nanjing 23
Brussels 22
Istanbul 22
San Diego 21
Redondo Beach 20
Jacksonville 19
Rome 17
São Paulo 16
Dakar 15
Dong Ket 15
Hefei 15
Ho Chi Minh City 15
Turku 14
Council Bluffs 13
Frankfurt am Main 13
Helsinki 13
Shenyang 13
Tokyo 13
Nanchang 12
Phoenix 12
Buffalo 11
Fuzhou 11
Alessandria 10
Düsseldorf 10
Toronto 10
Changsha 9
Hanoi 9
Hebei 9
Nuremberg 9
Redwood City 9
Rio de Janeiro 9
Warsaw 9
Boston 8
Campinas 8
Chicago 8
Duncan 8
Kunming 8
Monza 8
Tashkent 8
Atlanta 7
Brooklyn 7
Denver 7
Lagos 7
Washington 7
Columbus 6
Kocaeli 6
Ogden 6
San Jose 6
Stockholm 6
The Dalles 6
Chennai 5
Falkenstein 5
Guangzhou 5
Hangzhou 5
Jiaxing 5
Montreal 5
Nairobi 5
Orem 5
Palermo 5
Piracicaba 5
Pune 5
Westminster 5
Ankara 4
Boulder 4
Curitiba 4
Totale 5.233
Nome #
Prognostic Impact of TS, MTHFR and XRCC1 Genetic Variants in 113 Patients with Myelodysplastic Syndromes 247
Kinetics of hematogones in bone marrow samples from patients with non-Hodgkin lymphomas treated with rituximab-containing regimens: a flow cytometric study 237
Evaluation of the MDR1, ABCG2, Topoisomerases IIalpha and GSTpi gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen. Leuk Lymphoma 230
The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia 220
Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia 204
The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia 197
Evaluation of the MDR1, ABCG2, Topoisomerases IIalpha and GSTpi gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen 194
EXTENSIVE ANALYSIS OF T CELL RECEPTOR GAMMA (TCRG) GENE REARRANGEMENTS REVEALS A SIMILAR REPERTOIRE IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) AND IN HYPEREOSINOPHILIC SYNDROME (HES) 188
The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study 184
Combined unfavourable polymorphisms ofhOCT1 and ABCG2 are responsible for delayed complete cytogenetic response during imatinib treatment. 181
Polycomb genes are associated with response to imatinib in chronic myeloid leukemia 180
GTF2I mutations are common in thymic epithelial tumors but not in hematological malignancies 175
The combination of rituximab and bendamustine as first-line treatment is highly effective in the eradicating minimal residual disease in follicular lymphoma: An Italian retrospective study 174
TCR REARRANGEMENTS ARE NOT ENOUGH FOR DISTINGUISHING THE CHURG-STRAUSS SYNDROME FROM THE HYPEREOSINOPHILIC SYNDROME 173
Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: The FIL FOLL05 trial 170
No reactivation of JCV in bone marrow of follicular lymphoma patients treated front-line with rituximab plus 90y-ibritumomab tiuxetan 170
MDS: An Integrated Workup for a Correct Diagnosis 168
The WNT pathway is relevant for the BCR-ABL1-independent resistance in chronic myeloid leukemia 168
Ficoll-hypaque separation vs whole blood lysis: Comparison of efficiency and impact on minimal residual disease analysis 163
TCR GAMMA CLONALITY ASSESSED BY NGS DOES NOT HELP TO DISTINGUISH EGPA FROM HES 160
Comparison of Real-Time PCR and Droplet Digital PCR for the Determination of JAK2V617F Mutation in Ph'-Negative Myeloproliferative Neoplasms 156
Molecular detection of GNNK- and GNNK+ c-kit isoforms: a new tool for risk stratification in adult acute myeloid leukaemia 155
Myelodysplastic syndromes: advantages of a combined cytogenetic and molecular diagnostic workup 155
LOW RPS14 EXPRESSION IS FREQUENTLY FOUND IN NON-5Q-MYELODYSPLASTIC SYNDROMES 154
Combined FAMD and ANOVA investigation leads to significant association between the hOCT1/ABCB1 diplotype and both efficacy and tolerability in patients affected by chronic myeloid leukemia 144
The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients 144
Donor-transmitted Triple-Hit Lymphoma in a Renal Allograft Recipient 142
Altered Expression of Jak-Stat Pathway as Possible Predictive Marker in Patients Affected by Chronic Myeloid Leukemia Receiving Tyrosin Kinase Inhibitors (TKIS) 142
The Minimal Residual Disease in Non-Hodgkin's Lymphomas: From the Laboratory to the Clinical Practice 140
WT1 expression levels at diagnosis could predict long-term time-to-progression in adult patients affected by acute myeloid leukaemia and myelodysplastic syndromes 138
MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine 138
Sorafenib Induced Complete Cytogenetic and Molecular Response in a Chronic Eosinophilic Leukemia Case with t(12;13) Translocation 130
Vorinostat interferes with Wnt and NF-kappaB pathways in the M-07e cell line 128
Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation 126
Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network 123
Conventional Cytogenetics, ACGH, and PCR as Integrated Workup for a Correct Diagnosis of MDS 122
Defining TCRγδ lymphoproliferative disorders by combined immunophenotypic and molecular evaluation 122
Different gamma/delta T clones sustain GVM and GVH effects in multiple myeloma patients after non-myeloablative transplantation 121
R-IPSS, RPS14 AND WT1 LEVELS ARE THE BEST PROGNOSTIC FACTORS FOR PATIENTS AFFECTED BY MYELODYSPLASTIC SYNDROMES DURING AZACITIDINE TREATMENT. 118
TYROSINE KINASE INHIBITORS SIGNIFICANTLY CHANGE THE EXPRESSION OF POLYCOMB GENES IN CHRONIC MYELOID LEUKEMIA 115
Cell clonality in hypereosinophilic syndrome: what pathogenetic role? 114
Myelodysplastic Syndromes: A Multidisciplinary Integrated Diagnostic Work-up for Patients' Risk Stratification 112
THE C.480C>G POLYMORPHISM OF HOCT1 TRANSPORTER INFLUENCES IMATINIB CLEARANCE IN PATIENTS AFFECTED BY CHRONIC MYELOID LEUKEMIA 102
Real-Time PCR and Droplet Digital PCR: two techniques for detection of the JAK2(V617F) mutation in Philadelphia-negative chronic myeloproliferative neoplasms 100
Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study 89
Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma 88
Simultaneous presentation of Waldenström macroglobulinemia and multiple myeloma: multidisciplinary diagnosis, treatment and 30-month follow-up.sinensis leaf extract. 87
Comparison of different DNA extraction methods from peripheral blood cells: advice from the Fondazione Italiana Linfomi Minimal Residual Disease Network 81
The efficacy of rituximab plus Hyper-CVAD regimen in mantle cell lymphoma is independent of FCgammaRIIIa and FCgammaRIIa polymorphisms 78
Comparison of two real-time quantitative polymerase chain reaction strategies for minimal residual disease evaluation in lymphoproliferative disorders: Correlation between immunoglobulin gene mutation load and real-time quantitative polymerase chain reaction performance 77
Comparison of two real-time quantitative polymerase chain reaction strategies for minimal residual disease evaluation in lymphoproliferative disorders: correlation between immunoglobulin gene mutation load and real-time quantitative polymerase chain reaction performance 75
Human mesenchymal cells inhibit IL2 and zoledronate-induced gamma/delta T-cells 75
null 51
Totale 7.625
Categoria #
all - tutte 22.161
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.161


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021261 0 0 0 0 0 22 21 26 43 31 39 79
2021/2022670 15 32 12 39 111 92 24 17 70 28 53 177
2022/2023863 133 164 53 72 71 94 8 67 124 15 57 5
2023/2024494 55 39 66 31 52 86 28 12 6 19 24 76
2024/20251.731 6 60 11 99 198 202 174 114 145 218 178 326
2025/20261.268 136 247 285 218 213 169 0 0 0 0 0 0
Totale 7.625